Canadian Pacific Kansas City Limited Common Shares vs Nuwellis Inc — how do they compare? Canadian Pacific Kansas City Limited Common Shares trades at $84.17 (market cap $73.98B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Canadian Pacific Kansas City Limited Common Shares is far larger — about 33627.3× Nuwellis Inc's market cap, and Canadian Pacific Kansas City Limited Common Shares pays a 0.9% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| CP | NUWE | |
|---|---|---|
Market Cap | $73.98B | $2.20M |
Volume | 1,669,828 | 121,544 |
Sector | Industrials | Health |
52-Week High | $96.69 | $146.65 |
52-Week Low | $68.88 | $0.68 |
Enterprise Value | $91.36B | -$1.52M |
Dividend Yield | 0.9% | — |
Typical Hold Time | — | 26 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Canadian Pacific Kansas City operates a freight railway connecting Canada, the United States, and Mexico. The company was formed through the combination of Canadian Pacific and Kansas City Southern.
Read more on CP →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →